跳轉至內容
Merck
全部照片(1)

重要文件

檢視所有文件

A-903

Supelco

阿普唑仑标准液 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C17H13ClN4
CAS號碼:
28981-97-7
分子量：:
308.76
EC號碼:
200-659-6
MDL號碼:
MFCD00078881
分類程式碼代碼:
41116107
PubChem物質ID:
329771027
NACRES:
NA.24

等級

certified reference material

品質等級

300

形狀

liquid

特點

SNAP-N-SPIKE®, SNAP-N-SHOOT®

包裝

ampule of 1 mL

製造商／商標名

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

濃度

1.0 mg/mL in methanol

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

形式

single component solution

儲存溫度

−20°C

SMILES 字串

Cc1nnc2CN=C(c3ccccc3)c4cc(Cl)ccc4-n12

InChI

1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3

InChI 密鑰

VREFGVBLTWBCJP-UHFFFAOYSA-N

基因資訊

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

尋找類似的產品？ 前往 產品比較指南

一般說明

阿普唑仑是一种苯二氮卓类药物，可用于治疗焦虑症和恐慌症，包括广泛性或社交焦虑症。此认证的参考标准品通过LC/MS或GC/MS，可用于从法医分析和临床毒理学到尿液药物测试方面的各种应用中。阿普唑仑以商品名Xanax出售®。

應用


  • 阿普唑仑固体脂质纳米粒用于缓释：开发基于Compritol的阿普唑仑固体脂质纳米粒，为苯二氮䓬生物化学带来新的缓释制剂方法。该方法可保证药物控释并提升生物利用度，对抗焦虑物质药代学的改进有重要意义(Rao et al., 2022)。

  • 生物样本中阿普唑仑的提取：采用纳米石墨烯（α-吡啶胺接枝）进行阿普唑仑的分散固相萃取，有重要的法医和临床毒理学意义。该方法提高复杂生物基质中苯二氮䓬检测的精密度，对神经药理研究极具意义(Parsayi Arvand et al., 2023)。

  • 药物滥用分析中的拉曼光谱技术：利用便携式拉曼光谱技术检测药物滥用（包括阿普唑仑）。本文开发了阿普唑仑的快速无损检测方法，促进法庭科学发展(Santos et al., 2022)。

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Xanax is a registered trademark of Pharmacia & Upjohn Company

相關產品

產品號碼
描述
訂價

A-902

阿普唑仑-d5 溶液, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-904

alpha-Hydroxyalprazolam-d5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-907

α-羟阿普唑仑标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-908

alpha-Hydroxyalprazolam-d5 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-910

阿普唑仑-d5 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-033

8种苯二氮卓类混标 CRM 溶液, 250 μg/mL each component in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

IMF-020S

苯二氮卓类iMethod检测试剂盒（含合成尿液）, kit of 23 × 1.0 mL ampules, certified reference material, Cerilliant®

H-142

4-羟基阿普唑仑 溶液, 1 mg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

H-143

4-Hydroxyalprazolam-D5 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

F-095

Flualprazolam solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

F-096

Flualprazolam-D4 solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

B-108

Bromazolam solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes,Central nervous system

儲存類別代碼

3 - Flammable liquids

水污染物質分類（WGK）

WGK 2

閃點（°F）

49.5 °F - closed cup

閃點（°C）

9.7 °C - closed cup

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助，請聯絡 客戶支援

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Dean T Acheson et al.
Human psychopharmacology, 27(4), 419-427 (2012-07-12)
Heightened anticipation of future events has been characterized as a feature of certain anxiety disorders. In functional magnetic resonance imaging studies, anticipation of fearful/threatening images has been shown to robustly activate the insular cortex and amygdala in healthy subjects, in
J M Jonas et al.
The Journal of clinical psychiatry, 54 Suppl, 25-45 (1993-10-01)
A review of the worldwide published literature was conducted to assess the efficacy and safety of alprazolam for the treatment of anxiety disorders, panic disorder, and depression in comparison with those of other active drugs (including other benzodiazepines and antidepressant
E M Sellers et al.
The Journal of clinical psychiatry, 54 Suppl, 64-75 (1993-10-01)
The incidence of nonmedical use of alprazolam is very low relative to its widespread legitimate medical use; in fact, given the millions of patients who have received this medication, the incidence is remarkably small. In particular, among patients with anxiety
J O Cole et al.
The Journal of clinical psychiatry, 54 Suppl, 49-61 (1993-10-01)
A review of the published case reports of adverse behavioral episodes or unexpected psychopathology in patients taking benzodiazepines was undertaken in an attempt to determine if these adverse or unexpected events are more likely to occur with alprazolam when compared
Steven Moylan et al.
The Australian and New Zealand journal of psychiatry, 46(3), 212-224 (2012-03-07)
To investigate the potential impact of increasing prescription rates of alprazolam for the treatment of panic disorder (PD) in Australia through a review of efficacy, tolerability and adverse outcome literature. Data were sourced by a literature search using MEDLINE, Embase
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務